Volume 7, Issue 2 (Journal of Clinical and Basic Research (JCBR) 2023)
jcbr 2023, 7(2): 16-20 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
sheikh arabi M, Hoseini S Z. The potential of nanotechnology to combat the Covid-19 pandemic. jcbr 2023; 7 (2) :16-20
URL: http://jcbr.goums.ac.ir/article-1-370-en.html
URL: http://jcbr.goums.ac.ir/article-1-370-en.html
1- Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran , msheykharabi@yahoo.com
2- Biomaterials Research Group, Nanotechnology and Advanced Materials Department ,Materials and Energy Research Center (MERC), Tehran, Iran
2- Biomaterials Research Group, Nanotechnology and Advanced Materials Department ,Materials and Energy Research Center (MERC), Tehran, Iran
Abstract: (1205 Views)
In March 2020, the World Health Organization (WHO) announced that Coronavirus (2019) (COVID-19) was recognized as a global epidemic. In late 2019, a new type of the coronavirus family, known as Acute Respiratory Syndrome (SARS-CoV-2), emerged in Wuhan, China, and was named Covid-19. The COVID-19 epidemic has plunged the world into an unprecedented crisis, causing huge human and economic losses. As of July 6, 2020. The high rate of lung infection, long latency period, with mild to moderate symptoms or even cases that many people experience, or even cases of asymptomatic patients, has made Covid-19 a worrying disease. Challenges to treat the disease include vaccine design, high-speed mass production, and uniform worldwide distribution. Nanoparticles with their physicochemical properties can be a promising treatment method to win the battle against coronaviruses. Nanotechnology usually deals with the design and development of materials with dimensions of 1 nanometer to hundreds of nanometers, which makes it possible to design and manufacture materials with the desired structure and a controllable and small structure. In this review article, we explore the disease of Covid-19 and the potential of nanotechnology as a bright and promising pathway for the diagnosis, drug delivery, and treatment of Covid-19.
Article Type: Review |
Subject:
Basic medical sciences
References
1. Coleman CM, Liu Y v., Mu H, Taylor JK, Massare M, Flyer DC, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014 May 30;32(26):3169-74. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Coleman CM, Frieman MB. Coronaviruses: Important Emerging Human Pathogens. J Virol. 2014;88(10):5209-12. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. WHO. WHO announces COVID-19 outbreak a pandemic. 2020 Mar 12. [View at Publisher] [Google Scholar] [View at Publisher] [Google Scholar]
4. Lemon SM, Mahmoud AAF. The threat of pandemic influenza: are we ready? Biosecur Bioterror. 2005;3(1):70-3. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ. 2020;369:m1375. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. 2020;382(22):2163-4. [View at Publisher] [DOI] [PMID] []
8. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Abd Ellah NH, Gad SF, Muhammad K, E Batiha G, Hetta HF. Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. Nanomedicine [Lond]. 2020;15(21):2085-102. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Ahmadi S, Rabiee N, Bagherzadeh M, Elmi F, Fatahi Y, Farjadian F, et al. Stimulus-responsive sequential release systems for drug and gene delivery. Nano Today. 2020;34 [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Rabiee N, Bagherzadeh M, Ghadiri AM, Kiani M, Aldhaher A, Ramakrishna S, et al. Green Synthesis of ZnO NPs via Salvia hispanica: Evaluation of Potential Antioxidant, Antibacterial, Mammalian Cell Viability, H1N1 Influenza Virus Inhibition and Photocatalytic Activities. J Biomed Nanotechnol. 2020;16(4):456-66. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, et al. Rooting the Phylogenetic Tree of Middle East Respiratory Syndrome Coronavirus by Characterization of a Conspecific Virus from an African Bat. J Virol. 2014;88(19):11297-303. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 2012;3(6):e00473-12. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. An Overview of Nanotechnology Patents Focusing on Coronaviruses | STATNANO [Internet]. 2020. [View at Publisher] [Google Scholar]
15. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-24. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status. Mil Med Res. 2020;7(1):11. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Itani R, Tobaiqy M, Faraj A al. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics. 2020;10(13):5932-42. [View at Publisher] [DOI:10.7150/thno.46691] [PMID] [Google Scholar]
18. Rai M, Bonde S, Yadav A, Plekhanova Y, Reshetilov A, Gupta I, et al. Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints. Expert Rev Anti Infect Ther. 2022;20(10):1299-1308. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Uskoković V. Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic? Nanomedicine. 2020;15(17):1719-34. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020;17(7):765-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol. 2020;92(4):455-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Zhou P, Yang X lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. [View at Publisher] [DOI] [PubMed] [Google Scholar]
23. Zhang Y, Chen C, Zhu S, Shu C, Wang D, Song J, et al. Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19). China CDC Wkly. 2020;2(8):123-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Shen M, Zhou Y, Ye J, Abdullah AL-maskri AA, Kang Y, Zeng S, et al. Recent advances and perspectives of nucleic acid detection for coronavirus. J Pharm Anal. 2020;10(2):97-101. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. [View at Publisher] [DOI] [PubMed] [Google Scholar]
26. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Ucar F, Korkmaz D. COVIDiagnosis-Net: Deep Bayes-SqueezeNet based diagnosis of the coronavirus disease 2019 (COVID-19) from X-ray images. Med Hypotheses. 2020;140:109761. [View at Publisher] [DOI] [PMID] [Google Scholar]
28. He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. 2020;127:104361. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Vogl T, Leviatan S, Segal E. SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population. Cell Rep Med. 2021;2(2):100191. [View at Publisher] [DOI] [PMID] [Google Scholar]
30. Zhao Z, Cui H, Song W, Ru X, Zhou W, Yu X. A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. bioRxiv. 2020. [View at Publisher] [DOI] [PubMed] [Google Scholar]
31. Gong P, He X, Wang K, Tan W, Xie W, Wu P, et al. Combination of functionalized nanoparticles and polymerase chain reaction-based method for SARS-CoV gene detection. J Nanosci Nanotechnol. 2008;8(1):293-300. [View at Publisher] [DOI] [PMID] [Google Scholar]
32. Kim H, Park M, Hwang J, Kim JH, Chung DR, Lee KS, et al. Development of Label-Free Colorimetric Assay for MERS-CoV Using Gold Nanoparticles. ACS Sens. 2019;4(5):1306-12. [View at Publisher] [DOI] [PMID] [Google Scholar]
33. Martínez-Paredes G, González-García MB, Costa-García A. Genosensor for SARS Virus Detection Based on Gold Nanostructured Screen-Printed Carbon Electrodes. Electroanalysis. 2009;21(3-5):379-85. [View at Publisher] [DOI] [Google Scholar]
34. Ahmed SR, Nagy É, Neethirajan S. Self-assembled star-shaped chiroplasmonic gold nanoparticles for an ultrasensitive chiro-immunosensor for viruses. RSC Adv. 2017;7(65):40849-57. [View at Publisher] [DOI] [Google Scholar]
35. Layqah LA, Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchim Acta. 2019;186(4):224. [View at Publisher] [DOI] [PMID] [Google Scholar]
36. Ahmadi A, Mirzaeizadeh Z, Omidfar K. Simultaneous Detection of SARS-CoV-2 IgG/IgM Antibodies, Using Gold Nanoparticles-Based Lateral Flow Immunoassay. Monoclon Antib Immunodiagn Immunother. 2021;40(5):210-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
37. Xiang J, Yan M, Li H, Liu T, Lin C, Huang S, et al. Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19). medRxiv. 2020;PPR115301. [View at Publisher] [DOI] [Google Scholar]
38. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-3. [View at Publisher] [DOI] [PMID] [Google Scholar]
39. Huang P, Wang H, Cao Z, Jin H, Chi H, Zhao J, et al. A rapid and specific assay for the detection of MERS-CoV. Front Microbiol. 2018;9:1101. [View at Publisher] [DOI] [PMID] [Google Scholar]
40. Kim H, Park M, Hwang J, Kim JH, Chung DR, Lee K sung, et al. Development of Label-Free Colorimetric Assay for MERS-CoV Using Gold Nanoparticles. ACS Sens. 2019;4(5):1306-12. [View at Publisher] [DOI] [PMID] [Google Scholar]
41. Li H, Rothberg L. Colorimetric detection of DNA sequences based on electrostatic interactions with unmodified gold nanoparticles. Proc Natl Acad Sci U S A. 2004;101(39):14036-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
42. Xiang J, Yan M, Li H, Liu T, Lin C, Huang S, et al. Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19). medRxiv. 2020. PPR: PPR115301 [View at Publisher] [DOI] [PubMed] [Google Scholar]
43. Baker AN, Richards SJ, Guy CS, Congdon TR, Hasan M, Zwetsloot AJ, et al. The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device. ACS Cent Sci. 2020;6(11):2046-52. [View at Publisher] [DOI] [PMID] [Google Scholar]
44. Taher MA, Karami C, Sheikh Arabi M, Ahmadian H, Karami Y. Efficient FeCl 3 /SiO 2 as heterogeneous nanocatalysis for the synthesis of benzimidazoles under mild conditions. Int Nano Lett. 2016;6(2):85-90. [View at Publisher] [DOI] [Google Scholar]
45. Talebian S, Conde J. Why Go NANO on COVID-19 Pandemic? Matter. 2020;3(3):598-601. [View at Publisher] [DOI] [PMID] [Google Scholar]
46. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327-37. [View at Publisher] [DOI] [PMID] [Google Scholar]
47. Lugade AA, Bharali DJ, Pradhan V, Elkin G, Mousa SA, Thanavala Y. Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine. 2013;9(7):923-34. [View at Publisher] [DOI] [PMID] [Google Scholar]
48. Salvador A, Sandgren KJ, Liang F, Thompson EA, Koup RA, Pedraz JL, et al. Design and evaluation of surface and adjuvant modified PLGA microspheres for uptake by dendritic cells to improve vaccine responses. Int J Pharm. 2015;496(2):371-81. [View at Publisher] [DOI] [PMID] [Google Scholar]
49. Eidi H, Joubert O, Attik G, Duval RE, Bottin MC, Hamouia A, et al. Cytotoxicity assessment of heparin nanoparticles in NR8383 macrophages. Int J Pharm. 2010;396(1-2):156-65. [View at Publisher] [DOI] [PMID] [Google Scholar]
50. Diaz-Arévalo D, Zeng M. Nanoparticle-based vaccines: opportunities and limitations. Nanopharmaceuticals. 2020:135-50. [View at Publisher] [DOI] [PubMed] [Google Scholar]
51. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315-22. [View at Publisher] [DOI] [PMID] [Google Scholar]
52. Vallhov H, Qin J, Johansson SM, Ahlborg N, Muhammed MA, Scheynius A, et al. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett. 2006;6(8):1682-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
53. Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, et al. Type 1 and 2 Immunity Following Vaccination Is Influenced by Nanoparticle Size: Formulation of a Model Vaccine for Respiratory Syncytial Virus. Mol Pharm. 2006;4(1):73-84. [View at Publisher] [DOI] [PMID] [Google Scholar]
54. Wang XY, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release. 2007;119(2):236-44. [View at Publisher] [DOI] [PMID] [Google Scholar]
55. Ishida T, Wang XY, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349-55. [View at Publisher] [DOI] [PMID] [Google Scholar]
56. kheirollahpour M, Mehrabi M, Dounighi NM, Mohammadi M, Masoudi A. Nanoparticles and Vaccine Development. Pharm Nanotechnol. 2019;8(1):6-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
57. Chen HW, Huang CY, Lin SY, Fang ZS, Hsu CH, Lin JC, et al. Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection. Biomaterials. 2016;106:111-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
58. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
59. Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles with proteins: Relation to bio-reactivity of the nanoparticle. J Nanobiotechnology. 2013;11(1):26. [View at Publisher] [DOI] [PMID] [Google Scholar]
60. Dykman LA, Khlebtsov NG. Immunological properties of gold nanoparticles. Chem Sci. 2017;8(3):1719-35. [View at Publisher] [DOI] [PMID] [Google Scholar]
61. Ye S, Shao K, Li Z, Guo N, Zuo Y, Li Q, et al. Antiviral Activity of Graphene Oxide: How Sharp Edged Structure and Charge Matter. ACS Appl Mater Interfaces. 2015;7(38):21571-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
62. Chen YN, Hsueh YH, Hsieh C, Tzou DY, Chang PL. Antiviral Activity of Graphene-Silver Nanocomposites against Non-Enveloped and Enveloped Viruses. Int J Environ Res Public Health. 2016;13(4):430. [View at Publisher] [DOI:10.3390/ijerph13040430] [PMID] [Google Scholar]
63. Park SJ, Park HH, Kim SY, Kim SJ, Woo K, Ko GP. Antiviral properties of silver nanoparticles on a magnetic hybrid colloid. Appl Environ Microbiol. 2014;80(8):2343-50. [View at Publisher] [DOI] [PMID] [Google Scholar]
64. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology. 2005;3(1):6. [View at Publisher] [DOI] [PMID] [Google Scholar]
65. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8(1):1. [View at Publisher] [DOI] [PMID] [Google Scholar]
66. Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M. Silver Nanoparticles as Potential Antiviral Agents. Molecules. 2011;16(10):8894-918. [View at Publisher] [DOI] [PMID] [Google Scholar]
67. Łoczechin A, Séron K, Barras A, Giovanelli E, Belouzard S, Chen YT, et al. Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus. ACS Appl Mater Interfaces. 2019;11(46):42964-74. [View at Publisher] [DOI] [PubMed] [Google Scholar]
68. Cavalcanti IDL, Cajubá de Britto Lira Nogueira M. Pharmaceutical nanotechnology: which products are been designed against COVID-19? J Nanopart Res. 2020;22(9):276. [View at Publisher] [DOI] [PMID] [Google Scholar]
69. Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017;35(12):1586-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
70. Kato T, Takami Y, Kumar Deo V, Park EY. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. J Biotechnol. 2019;306:177-84. [View at Publisher] [DOI] [PMID] [Google Scholar]
71. Wang C, Zheng X, Gai W, Wong G, Wang H, Jin H, et al. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res. 2017;140:55-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
72. Kim YS, Son A, Kim J, Kwon S bin, Kim MH, Kim P, et al. Chaperna-mediated assembly of ferritin-based middle East respiratory syndrome-coronavirus nanoparticles. Front Immunol. 2018;9:1093. [View at Publisher] [DOI] [PMID] [Google Scholar]
73. Pimentel TAPF, Yan Z, Jeffers SA, Holmes KV, Hodges RS, Burkhard P. Peptide Nanoparticles as Novel Immunogens: Design and Analysis of a Prototypic Severe Acute Respiratory Syndrome Vaccine. Chem Biol Drug Des. 2009;73(1):53-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
74. Sekimukai H, Iwata-Yoshikawa N, Fukushi S, Tani H, Kataoka M, Suzuki T, et al. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol Immunol. 2020;64(1):33-51. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).